The Court held that the declared intention to launch a biosimilar drug and the obtaining of the related Marketing Authorization did not constitute an "imminent infringement" of the patent on the originator drug. Therefore, the requested interim injunction was not granted.

The court elaborated on when two parties are to be considered the “same parties” under Article 33 UPCA, based on which, if an action for infringement between the same parties relating to the same patent has been brought before a local or a regional division, the revocation action may only be brought before the same local or regional division.

The CD ordered the claimant in a revocation action to pay a security of € 300,000 for the defendant’s legal costs, based on its financial position and the alleged difficulties in enforcing a cost decision in the UK.